Nipro newsletter April 2026
Carterra 23/09/25
LB Bohle – 10.06.2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

DDL 2026
Merxin March 2026
Terumo 05/01
SAE Media – Pre-filled syringes West Coast 19/11/25
Nipro April 2026

NNIT wins five-year international infrastructure outsourcing agreement with global life science company

NNIT, a leading provider of IT services and consultancy, announces that it has signed its first global infrastructure outsourcing agreement within the international life science industry segment.
 
The agreement covers global services including support and maintenance of the global IT infrastructure for Lonza, one of the world’s leading and most-trusted pharmaceutical, biotech and specialty ingredients markets’ suppliers.
 
“Signing with Lonza marks an important milestone in NNIT’s vision of becoming a trusted provider of regulated IT for life sciences worldwide,” says Per Kogut, CEO at NNIT. He continues: “We are proud to outmatch major IT-infrastructure outsourcing competitors and realizing our strategic ambition.”
 
Lonza has more than 50 major manufacturing and R&D facilities and 14,000 full-time employees worldwide across 90 sites in 30 countries. Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. 
 
“In NNIT we have found a partner with a strong legacy in life sciences who acknowledges the requirements for critical infrastructure and understands what it takes to comply. We are particularly impressed with NNIT’s GxP validated setup and the full stack of services,” explains Ernst Hutter, Head of Corporate IT Infrastructure Services at Lonza.
 
The infrastructure outsourcing agreement covers remote management of two datacentres in Switzerland, and Lonza has the option to gradually move to NNIT datacentres when procuring new services. Furthermore, NNIT will manage all remote LAN and servers & storage globally, including 13 production sites with GxP (good Quality Practice guidelines) requirements.
SMI London
Biopharma group march 2026
Silgan March 2026
Scott Pharma – 25.03.2025
Bespak – 21.05.2025
Aptar – 08/01/2026
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025